Several of our experts have identified the healthcare sector as a powerful profit play. But where should you invest within the industry? Which Big Pharma plays offer the right combination of growth and income? And where can you strike it rich in the ever-shifting biotechnology space? Find out from our sector experts in this enlightening and actionable panel discussion.
- If the Fed cuts rates again in 2026, we could be posed for one of the largest outperformance events for SMIDs in a decade
- Join Erin as she discusses the importance of investing in smaller US companies – especially as the Mag 7 leadership loses steam
- It has been quite some time since we had strong outperformance in SMIDs…but Erin will remind you why, sometimes, investing in America’s smaller companies can spin off larger rewards